Vietnam Oncology Therapeutics Market Report 2022 to 2030

Vietnam Oncology Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Vietnam Oncology Therapeutics Market will reach a value of $1.8 Bn from $0.91 Bn in 2022, growing at a CAGR of 8.6% during 2022-2030. The Oncology Therapeutics Market in Vietnam is dominated by a few domestic pharmaceutical companies such as Hau Giang Pharmaceutical, Vietnam Pharma, and Pymepharco. The Oncology Therapeutics Market in Vietnam is segmented into different types of cancer and different therapy type. The major risk factors associated with cancer are diet, alcohol, tobacco, air pollution, and physical inactivity. The demand for Vietnam Oncology Therapeutics is increasing on account of the rise in initiatives taken by the Government of the country.

ID: IN10VNPH042 CATEGORY: Pharmaceuticals GEOGRAPHY: Vietnam AUTHOR: Dr. Vishwa Modhia

Buy Now

Vietnam Oncology Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Vietnam Oncology Therapeutics Market will reach a value of $1.8 Bn from $0.91 Bn in 2022, growing at a CAGR of 8.6% during 2022-30.

Vietnam, a low–middle-income Southeast Asian country with a population of 96.5 Mn, is the 15th most populous country in the world. In Vietnam, the anticipated number of new cases in 2018 was 1,64,671 (0.17 % of the population), with a total of 1,14,871 deaths (0.12 % of the population). In the last 30 years, both statistics have tripled. Vietnam introduced the National Cancer Control Programme (NCCP) in 2002,9 implemented it in 2008,7 and reaffirmed its commitment to this programme in the national policy for noncommunicable disease prevention and control (NCDs).

The cancer control plan aims to promote community knowledge about cancer prevention and early detection, increase the number of early-diagnosed cancer cases, and lower mortality rates for breast, cervical, oral, and colorectal cancer from 2012 to 2015. Vietnam's government spends 4.7% of its GDP on healthcare.

Vietnam Oncology Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

In Vietnam, the government is required to set aside 30% of the annual health budget for preventive medicine, while the remaining 70% is supposed to go toward tertiary care. With such a large investment, cancer care in Vietnam has seen great improvement in recent years, with the number of radiotherapy units and oncology departments steadily increasing throughout the country. Vietnamese Cancer Society (VCS) is a professional organisation where most cancer specialists in Vietnam come together to fight cancer. Cancer is becoming more widespread in Vietnam, with the National Cancer Institute expecting a more than quadrupling of cancer cases by 2030. These aspects could boost Vietnam Oncology Therapeutics Market.

Market Restraints

The quality of the national cancer registry data used as input to produce the numbers above has significant flaws. For example, there is a scarcity of national statistics on cancer survivorship and mortality. High smoking rates, a lack of cancer screening programmes, limited access to optimal therapy, and reimbursement constraints are all existing impediments. In Vietnam, defects in the business climate might make doing business difficult due to worries about data transparency and corruption perceptions. These factors may deter new entrants into the Vietnam Oncology Therapeutics Market.

Competitive Landscape

Key Players

Hau Giang Pharmaceutical Joint Stock Company (DHG Pharma): DHG Pharma is a Vietnamese pharmaceutical company that produces a range of cancer therapeutics, including chemotherapy drugs and targeted therapies. The company has a strong focus on research and development and has several innovative cancer drugs that are currently in clinical development
Vietnam Pharma Joint Stock Company (VAP): VAP is a Vietnamese pharmaceutical company that produces a range of cancer therapeutics, including chemotherapy drugs and targeted therapies. The company has a strong presence in the Vietnamese market and is expanding into other countries in Southeast Asia
DHG HATIPHARMA: DHG HATIPHARMA is a Vietnamese pharmaceutical company that produces a range of cancer therapeutics, including chemotherapy drugs and targeted therapies. The company has a strong focus on research and development and has several innovative cancer drugs that are currently in clinical development
Pymepharco Joint Stock Company: Pymepharco is a Vietnamese pharmaceutical company that produces a range of cancer therapeutics, including chemotherapy drugs and targeted therapies

Notable Recent Deals

March 2022: Roche Pharma Vietnam and the HCM City Cancer Hospital have reached an agreement to improve the professional ability of the hospital's medical personnel and to expand collaboration with domestic and international oncology organisations and specialists. The Memorandum of Understanding aims to improve diagnostic and therapeutic capacity, treatment, and patient support while also exchanging experience among international organisations, implementing key projects on breast, lung, and liver cancer, and developing a database for patient treatment and care.

Healthcare Policies and Reimbursement Scenarios

The regulation and reimbursement of cancer therapeutics in Vietnam are overseen by several entities, including the Ministry of Health and the Vietnam Social Security (VSS). The Drug Administration of Vietnam (DAV), which is part of the Ministry of Health, is the regulatory organisation in charge of cancer drug licencing and regulation in Vietnam. In Vietnam, the administrative body liable for the endorsement and guidelines of restorative items, including disease therapeutics, is the Ministry of Health (MOH). In the public medical care framework, the expense of malignant growth therapies, including malignant growth therapeutics, is mostly covered by the Health care coverage Fund for the Poor (HIFP) and the Health Insurance Fund for Formal Sector Employees (HIFSE).

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Oncology Therapeutics Segmentation

By Application (Revenue, USD Billion):

Blood Cancer
?Colorectal Cancer
Gastrointestinal Cancer
Gynaecologic Cancer
Breast Cancer
Lung Cancer
Prostate Cancer
?Others

By Drugs (Revenue, USD Billion):

Revlimid
Avastin
Herceptin
Rituxan
Opdivo
Gleevec
Velcade
Imbruvica
Ibrance
Zytiga
Alimta
Xtandi
Tarceva
Perjeta
Temodar
Others

By Therapy (Revenue, USD Billion):

Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Others

By Route of Administration (Revenue, USD Billion):

Oral
Parenteral
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
?Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.